trastuzumab duocarmazine
Selected indexed studies
- Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). (J Clin Oncol, 2025) [PMID:39442070]
- Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). (Eur J Med Chem, 2019) [PMID:31563805]
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. (Lancet Oncol, 2019) [PMID:31257177]
_Worker-drafted node — pending editorial review._
Connections
trastuzumab duocarmazine is a side effect of
Sources
- Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). (2025) pubmed
- Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). (2019) pubmed
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. (2019) pubmed
- Cancer du sein HER2-low : comment un concept biologique s’immisce-t-il dans la décision thérapeutique ?: HER2-low breast cancer: how does a biological concept interfere in therapeutic decision? (2021) pubmed
- « HER2-faible », un nouveau concept dans la prise en charge des cancers du sein: HER2-low breast cancer: a new concept in breast cancer treatment strategy. (2021) pubmed
- New ADC Shrinks HER2-Positive Tumors. (2019) pubmed
- Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database. (2022) pubmed
- How we treat patients with metastatic HER2-positive breast cancer. (2022) pubmed
- Antibodies to watch in 2019. (2019) pubmed
- Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. (2020) pubmed